Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Intellia Thera CS (NTLA)
Intellia Thera CS (NTLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,334,699
  • Shares Outstanding, K 89,555
  • Annual Sales, $ 52,120 K
  • Annual Income, $ -474,190 K
  • 60-Month Beta 1.74
  • Price/Sales 44.87
  • Price/Cash Flow N/A
  • Price/Book 2.12
Trade NTLA with:

Options Overview Details

View History
  • Implied Volatility 79.26% ( -0.04%)
  • Historical Volatility 52.73%
  • IV Percentile 96%
  • IV Rank 87.56%
  • IV High 84.12% on 02/21/23
  • IV Low 45.07% on 09/20/23
  • Put/Call Vol Ratio 0.23
  • Today's Volume 958
  • Volume Avg (30-Day) 721
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 18,277
  • Open Int (30-Day) 20,445

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -1.47
  • Number of Estimates 12
  • High Estimate -1.01
  • Low Estimate -1.66
  • Prior Year -1.40
  • Growth Rate Est. (year over year) -5.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.63 +16.25%
on 02/01/24
29.95 -8.28%
on 01/09/24
-2.60 (-8.65%)
since 01/08/24
3-Month
22.67 +21.20%
on 11/13/23
33.60 -18.24%
on 12/14/23
-0.98 (-3.44%)
since 11/08/23
52-Week
22.67 +21.20%
on 11/13/23
47.48 -42.14%
on 06/14/23
-15.64 (-36.28%)
since 02/08/23

Most Recent Stories

More News
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The widely followed growth investor keeps making moves.

PLTR : 24.51 (+3.86%)
TSLA : 189.56 (+1.06%)
NTLA : 27.47 (+5.37%)
A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist

These biotech innovators have what it takes to soar.

IOVA : 8.68 (+7.56%)
NTLA : 27.47 (+5.37%)
History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does.

Bull markets generally favor growth stocks, so now is a great time to buy quality growth players.

CRSP : 68.83 (+4.73%)
RJF : 112.10 (+0.95%)
AMZN : 169.84 (-0.40%)
NTLA : 27.47 (+5.37%)
PLTR : 24.51 (+3.86%)
2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street

Expectations for these stocks are sky-high, but so are the risks.

DNA : 1.3000 (+4.84%)
NTLA : 27.47 (+5.37%)
Is It Too Late to Buy Intellia Therapeutics Stock?

2024 could be an important year for the biotech.

NTLA : 27.47 (+5.37%)
Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics

Both companies are going to continue doing high-impact science in 2024.

NTLA : 27.47 (+5.37%)
CRSP : 68.83 (+4.73%)
The Top Healthcare Stocks to Buy With $100

These companies are shaping the healthcare of tomorrow.

TDOC : 20.38 (+1.85%)
NTLA : 27.47 (+5.37%)
MDT : 86.18 (-1.12%)
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics

These two are at very different stages of the clinical trials process.

EDIT : 7.17 (+0.84%)
NTLA : 27.47 (+5.37%)
4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024

Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run.

ARKK : 48.44 (+2.69%)
ARKW : 74.61 (+2.42%)
GH : 22.39 (+1.40%)
ARKG : 29.87 (+2.82%)
BEAM : 28.11 (+1.96%)
DNA : 1.3000 (+4.84%)
NTLA : 27.47 (+5.37%)
2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics

Curing rare inherited illnesses could be a lucrative business model.

CRSP : 68.83 (+4.73%)
NTLA : 27.47 (+5.37%)
VERV : 11.81 (+7.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the...

See More

Key Turning Points

3rd Resistance Point 30.13
2nd Resistance Point 29.02
1st Resistance Point 28.24
Last Price 27.47
1st Support Level 26.35
2nd Support Level 25.24
3rd Support Level 24.46

See More

52-Week High 47.48
Fibonacci 61.8% 38.00
Fibonacci 50% 35.07
Fibonacci 38.2% 32.14
Last Price 27.47
52-Week Low 22.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar